JP2019535315A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535315A5 JP2019535315A5 JP2019546073A JP2019546073A JP2019535315A5 JP 2019535315 A5 JP2019535315 A5 JP 2019535315A5 JP 2019546073 A JP2019546073 A JP 2019546073A JP 2019546073 A JP2019546073 A JP 2019546073A JP 2019535315 A5 JP2019535315 A5 JP 2019535315A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fusion protein
- antibody molecule
- amino acid
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims 14
- 102000037865 fusion proteins Human genes 0.000 claims 14
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 108010002350 Interleukin-2 Proteins 0.000 claims 7
- 102000000588 Interleukin-2 Human genes 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102000057041 human TNF Human genes 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 4
- 102000016359 Fibronectins Human genes 0.000 claims 3
- 108010067306 Fibronectins Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000000062 kidney sarcoma Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1618888.0 | 2016-11-09 | ||
| GB201618888 | 2016-11-09 | ||
| GBGB1712916.4A GB201712916D0 (en) | 2017-08-11 | 2017-08-11 | IL2 and TNF mutant immunoconjugates |
| GB1712916.4 | 2017-08-11 | ||
| PCT/EP2017/078652 WO2018087172A1 (en) | 2016-11-09 | 2017-11-08 | Il2 and tnf mutant immunoconjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535315A JP2019535315A (ja) | 2019-12-12 |
| JP2019535315A5 true JP2019535315A5 (enExample) | 2021-07-26 |
| JP6925431B2 JP6925431B2 (ja) | 2021-08-25 |
Family
ID=60413164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546073A Active JP6925431B2 (ja) | 2016-11-09 | 2017-11-08 | Ｉｌ２及びｔｎｆ突然変異体のイムノコンジュゲート |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11103592B2 (enExample) |
| EP (2) | EP3538547B1 (enExample) |
| JP (1) | JP6925431B2 (enExample) |
| AU (1) | AU2017358578B2 (enExample) |
| CA (1) | CA3043146C (enExample) |
| ES (1) | ES2893249T3 (enExample) |
| MX (1) | MX385819B (enExample) |
| NZ (1) | NZ754407A (enExample) |
| RU (1) | RU2758139C2 (enExample) |
| WO (1) | WO2018087172A1 (enExample) |
| ZA (1) | ZA201903387B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3502139A1 (en) | 2017-12-19 | 2019-06-26 | Philogen S.p.A. | Antibodies to tumour antigens |
| EP3584258A1 (en) * | 2018-06-19 | 2019-12-25 | IEO - Istituto Europeo di Oncologia Srl | Antibodies anti tumor associated antigens and method for obtaining them |
| CA3104185A1 (en) | 2018-07-02 | 2020-01-09 | The General Hospital Corporation | Antibody tumor-targeting assembly complexes |
| WO2020070150A1 (en) * | 2018-10-02 | 2020-04-09 | Philogen S.P.A | Il2 immunoconjugates |
| EP3660039A1 (en) * | 2018-11-30 | 2020-06-03 | Philogen S.p.A. | Il2 immunoconjugates |
| AU2019402097A1 (en) | 2018-12-17 | 2021-06-10 | Revitope Limited | Twin immune cell engager |
| CA3138854A1 (en) | 2019-05-02 | 2020-11-05 | The General Hospital Corporation | Teac and attac immunooncology compositions and methods |
| WO2020249757A1 (en) | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha |
| WO2022018126A1 (en) | 2020-07-22 | 2022-01-27 | Philogen S.P.A. | Treatment of pulmonary hypertension |
| KR102614063B1 (ko) * | 2020-12-24 | 2023-12-19 | 대화제약 주식회사 | 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체 |
| WO2023050826A1 (en) * | 2021-09-28 | 2023-04-06 | Suzhou Fuse Biosciences Limited | Immunoconjugates containing tnf-alpha and related methods and compositions thereof |
| US20250197485A1 (en) | 2022-03-17 | 2025-06-19 | Universitätsklinikum Jena | Anti-ED-A Antibodies for the Treatment of Pulmonary Hypertension |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4879226A (en) | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| AU1346488A (en) | 1987-02-26 | 1988-09-26 | Cetus Corporation | Arginine-depleted human tumor necrosis factor |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| CA2055168A1 (en) | 1990-11-21 | 1992-05-22 | Walter Fiers | Tnf-muteins |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| CA2399866C (en) | 2000-02-24 | 2011-05-10 | Philogen S.R.L. | Compositions and methods for treatment of angiogenesis in pathological lesions |
| US7101974B2 (en) | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
| IT1317108B1 (it) | 2000-12-06 | 2003-05-26 | Philogen Srl | Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso. |
| AU2002233340B2 (en) * | 2001-02-19 | 2008-05-22 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| SI1817345T1 (sl) | 2004-11-09 | 2009-10-31 | Philogen Spa | Protitelesa proti tenascinu-C |
| CA2849033C (en) * | 2011-09-26 | 2020-05-05 | Philogen S.P.A. | Immunocytokine combination therapy |
| BR112016001114B1 (pt) * | 2013-07-19 | 2023-02-14 | Vib Vzw | Composição compreendendo uma proteína de fusão e uso da referida composição |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
| GB201507908D0 (en) | 2015-05-08 | 2015-06-24 | Philogen Spa | IL2 and TNF immunoconjugates |
-
2017
- 2017-11-08 RU RU2019117750A patent/RU2758139C2/ru active
- 2017-11-08 NZ NZ754407A patent/NZ754407A/en unknown
- 2017-11-08 EP EP17801386.8A patent/EP3538547B1/en active Active
- 2017-11-08 MX MX2019005242A patent/MX385819B/es unknown
- 2017-11-08 CA CA3043146A patent/CA3043146C/en active Active
- 2017-11-08 WO PCT/EP2017/078652 patent/WO2018087172A1/en not_active Ceased
- 2017-11-08 US US16/348,371 patent/US11103592B2/en active Active
- 2017-11-08 JP JP2019546073A patent/JP6925431B2/ja active Active
- 2017-11-08 ES ES17801386T patent/ES2893249T3/es active Active
- 2017-11-08 EP EP21171564.4A patent/EP3896084A1/en active Pending
- 2017-11-08 AU AU2017358578A patent/AU2017358578B2/en active Active
-
2019
- 2019-05-28 ZA ZA2019/03387A patent/ZA201903387B/en unknown
-
2021
- 2021-07-23 US US17/384,207 patent/US20210369857A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535315A5 (enExample) | ||
| RU2019117750A (ru) | Иммуноконъюгаты il2 и мутантного tnf | |
| JP7140861B2 (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| JP2020517287A5 (enExample) | ||
| JP7116736B2 (ja) | 操作されたヘテロ二量体タンパク質 | |
| CY1116037T1 (el) | Αντισωματα κατα της ακτιβινης α και χρησεις αυτων | |
| JP2017525698A5 (enExample) | ||
| JP2014518615A5 (enExample) | ||
| MX2023005420A (es) | Anticuerpo bcma humanizado y linfocitos t car-bcma. | |
| JP2014158485A5 (enExample) | ||
| JPWO2019246004A5 (enExample) | ||
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| JP2017504578A5 (enExample) | ||
| JP2017520575A5 (enExample) | ||
| JP2018529321A5 (enExample) | ||
| JP2017509323A5 (enExample) | ||
| JP2012519492A5 (enExample) | ||
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| JP2018530331A5 (enExample) | ||
| Nilvebrant et al. | Selection and in vitro characterization of human CD44v6‐binding antibody fragments | |
| HRP20161449T1 (hr) | Genski proizvodi koji su diferecijalno izraženi u tumorima i njihova primjena | |
| US20220056146A1 (en) | Antibodies and Antigen Binding Fragments Against CD155 Methods of Use Thereof | |
| Fierle et al. | Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery | |
| JP2021514648A (ja) | 新規の標的抗原結合部分のための特異性アッセイ | |
| CN101440130A (zh) | 一种抗人IL-13Rα2单克隆抗体的重链和轻链的可变区 |